Sigma Labs Announces Full Year 2018 Financial Results
Conference call today, April 1, 2019 at 9:00 am eastern time
SANTA FE, N.M. – April 1, 2019 – Sigma Labs, Inc. (NASDAQ: SGLB) (“Sigma Labs” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, today announced financial results for the fiscal year ended December 31, 2018.
Highlights for 2018 and 2019 Developments
| ● | Demonstrated proof of concept for closed loop quality control during metal additive manufacturing. Using Sigma’s PrintRite3D® technology, the system operates by monitoring the process output and extracting process metrics. The process metrics are then compared to baseline metrics. The system then determines what process input parameter values need to be changed and implements those remedial changes in real time. | |
| ● | Launched PrintRite3D® 4.0 Product Suite with its patent-applied-for TED and TEP features enabling rapid AM machine optimization (TED) and in process quality assurance including signatures of precursors of developing quality anomalies (TEP). | |
| ● | Concurrent with the PrintRite3D® 4.0 release, the Company introduced its Rapid Test and Evaluation Program enabling qualifying customers to “try before they buy.” | |
| ● | Entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Standards and Technology (NIST) to help develop Additive Metal Manufacturing Standards in the U.S. | |
| ● | Awarded contract for its PrintRite3D® hardware, software and engineering services by a federally funded organization involved in the space industry. | |
| ● | Awarded a Rapid Test and Evaluation Program contract with a leading global materials and service provider in additive manufacturing (AM). | |
| ● | Awarded Rapid Test and Evaluation Program contract win in the Oil and Gas Industry with a leading provider of integrated oilfield products, services and digital solutions. | |
| ● | Awarded three U.S. Patents, US 9,999,924, US 10,207,489 and US 10,226,817, that provide protections for methods of assuring part quality using real time data from multiple sensor types. | |
| ● | Closed offerings for total gross proceeds of $5,351,220; $3,390,100 in 2018 and $1,961,120 in 2019. |
| ● | Darren Beckett and Dr. Martin Piltch assumed responsibilities of retiring CTO and Founder, Mark Cola. | |
| ● | Hired a Germany-based Business Development Manager and a London based Applications Engineer to facilitate our continued expansion into the European market. | |
| ● | Hired a U.S.-based Business Development Manager, North and South America. | |
| ● | Joined Manufacturing Technology Centre to advance industrialization of Additive Manufacturing with in-process quality control. | |
| ● | Sigma Labs and Fraunhofer IAPT announced a collaborative research and development agreement to test and validate the use of the PrintRite3D’s In-Process-Quality-Assurance suite to identify and quantify machine and process inconsistencies as well as to define in-process defect thermal signatures in the part formation process and correlate them to CT scan results. Also named a member of the Additive Alliance of Fraunhofer IAPT, a leading network for Additive Manufacturing (AM). As the first US company to be granted a membership in the Alliance, Sigma Labs becomes part of the global research consortium to advance the development and implementation of AM. |
“2018 was a momentous and, we believe, decisive year for our company. We completed a 17-month transition from an R&D company fielding an R&D tool into a Technology Commercialization company that introduced a commercial-industrial version of our PrintRite3D in November 2018. Sigma then commenced rolling out this technology through a Rapid Test and Evaluation Program directed at companies that manufacture or buy metal 3D manufactured parts and demand quality assurance solutions to improve yields and product risks that are below their companies’ high standards,” said John Rice, CEO of Sigma Labs. “The release to market of our TED and TEP tools was a seminal moment for us as it means that now we can give our customers the ability to identify inherent ‘built-in’ inconsistencies in 3D metal manufacturing equipment performance, allowing them to immediately address these inconsistencies, and we can discern the signatures of precursors of quality anomalies in real time before most of these first emerging problems spoil part quality. In 2018, we announced our successful proof of concept of closed loop control. Our Ted and TEP tools are essential for discerning and characterizing the information required by a closed loop control system. We are pleased with our progress and our pathway here.”
“In 2018, we also entered into and expanded our customer footprint in new industry verticals, including the Oil and Gas industry, as we implemented our increasingly successful Rapid Test and Evaluation Program approach to market growth. We also were awarded a contract for hardware, software and engineering services by a federally funded organization involved in the space industry. In order to expand our international sales opportunities, we hired a Business Development Manager who headquarters in Munich, Germany, an Applications Engineer who headquarters in Kingston upon Hull, England and a Business Development Manager for the Americas. While U.S. manufacturing employment has declined over the past 25 years, the future outlook for technologies like 3D metal manufacturing appears to be very bright. Taken alone, the U.S. manufacturing sector would be the ninth-largest economy in the world, according to the National Association of Manufacturers, in a new report issued by IndustryWeek Custom Research and Kronos Incorporated. To achieve their growth targets, manufacturers are investing in areas that will improve productivity and speed responsiveness and Sigma Labs now has a suite of products and services that can meet important unfilled niches of these needs,” Mr. Rice concluded.
2018 Full Year Financial Results
During the fiscal year ended December 31, 2018, we recognized revenue of $388,574 as compared to $641,049 recognized in 2017, a $252,475 reduction resulting from the shift from an emphasis on government and private industry funded research and development sales to our Rapid Test and Evaluation Program (“RTEP”).
Cost of sales for 2018 were $270,107 as compared to $272,372 in 2017, a decrease of $2,265. This results from a combination of higher optics and software systems costs of our PrintRite3D® 4.0 Product Suite and the additional travel costs associated with the onsite collaboration required with RTEP.
Sigma’s operating expenses for that twelve months ended December 31, 2018, were $5,687,271 as compared to $4,267,654 for the twelve months of fiscal 2017, a $1,419,617 increase. This increase resulted primarily from a combination of the requisite increase in salary and related costs of a 33% increase in employee count, the accrual of severance costs under executive employment agreement, increased internal R&D costs, higher travel cost for both business development outreach and onsite collaboration activities of RTEP and a more robust stock-based compensation program for both directors and employees in 2018.
The combination of lower sales revenue, higher cost of product and increased operations costs, discussed above, resulted in an operating loss of $5,568,804 in 2018 compared to a loss of $4,051,990 in 2017.
In 2018, our net other income and expense was a net expense of $5,359 compared to net expense of $525,526 in 2017. The 2017 expense was largely due to the non-cash adjustments required for the revaluation of derivatives and amortization of debt discounts related to debt and equity financing activities in that year.
As of December 31, 2018, we had $1,279,782 in cash and had a working capital surplus of $1,747,836, as compared with $1,515,674 in cash and a working capital surplus of $2,656,695 as of December 31, 2017.
Investor Conference Call
Management will host a conference call today, April 1, 2019 at 9:00 am eastern time to review financial results and corporate highlights. Following management’s formal remarks, there will be a question and answer session.
To listen to the call by phone, interested parties within the U.S. should call 1-844-802-2441 and International callers should call 1-412-317-5134. All callers should ask for the Sigma Labs conference call. The conference call will also be available through a live webcast at www.sigmalabsinc.com. Details for the webcast may be found on the Company’s IR events page at: http://client.irwebkit.com/sigmalabsinc/events.
A replay of the call will be available approximately one hour after the end of the call through May 1, 2019. The replay can be accessed via Sigma Labs’ website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10129976. The webcast replay will be available through July 1, 2019.
About Sigma Labs
Sigma Labs, Inc. is a provider of quality assurance software under the PrintRite3D® brand and a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. For more information please visit us at www.sigmalabsinc.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K (including but not limited to the discussion under “Risk Factors” therein) filed with the SEC on April 17, 2018 and which may be viewed at http://www.sec.gov.
Investor Relations Contact:
Bret Shapiro
Managing Director
CORE IR
561-479-8566
brets@coreir.com
Sigma Labs, Inc.
Condensed Balance Sheets
(Unaudited)
December 31, 2018 | December 31, 2017 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash | $ | 1,279,782 | $ | 1,515,674 | ||||
| Accounts Receivable, net | 38,800 | 104,538 | ||||||
| Note Receivable, net | 121,913 | 788,500 | ||||||
| Inventory | 240,086 | 192,705 | ||||||
| Prepaid Expenses | 67,255 | 55,278 | ||||||
| Total Current Assets | 1,747,836 | 2,656,695 | ||||||
| Other Assets: | ||||||||
| Property and Equipment, net | 277,944 | 411,643 | ||||||
| Intangible Assets, net | 404,978 | 294,396 | ||||||
| Investment in Joint Venture | 500 | 500 | ||||||
| Prepaid Stock Compensation | - | 31,576 | ||||||
| Total Other Assets | 683,422 | 738,115 | ||||||
| TOTAL ASSETS | $ | 2,431,258 | $ | 3,394,810 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts Payable | $ | 217,488 | $ | 100,884 | ||||
| Dividends Payable - Preferred | - | - | ||||||
| Notes Payable, net | 50,000 | 100,000 | ||||||
| Deferred Revenue | 51,498 | 35,680 | ||||||
| Accrued Expenses | 376,833 | 146,330 | ||||||
| Total Current Liabilities | 695,819 | 382,894 | ||||||
| TOTAL LIABILITIES | 695,819 | 382,894 | ||||||
| Stockholders’ Equity | ||||||||
| Preferred Stock, $0.001 par; 10,000,000 shares authorized; 0 shares issued and outstanding | - | - | ||||||
| Common Stock, $0.001 par; 22,500,000 shares authorized; 8,776,629, and 4,978,929 issued and outstanding, respectively | 8,777 | 4,979 | ||||||
| Additional Paid-In Capital | 21,501,407 | 17,192,394 | ||||||
| Accumulated Deficit | (19,774,745 | ) | (14,185,457 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | 1,735,439 | 3,011,916 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 2,431,258 | $ | 3,394,810 | ||||
Sigma Labs, Inc.
Condensed Statements of Operations
(Unaudited)
| Twelve Months Ended | ||||||||
| December 31, 2018 | December 31, 2017 | |||||||
| REVENUES | $ | 388,574 | $ | 641,049 | ||||
| COST OF REVENUES | 270,107 | 272,372 | ||||||
| GROSS PROFIT (Loss) | 118,467 | 368,677 | ||||||
| EXPENSES | ||||||||
| Salaries & Benefits | 2,056,584 | 1,509,672 | ||||||
| Stock-Based Compensation | 1,145,530 | 719,796 | ||||||
| Operating & R&D Costs | 493,410 | 302,043 | ||||||
| Investor & Public Relations | 633,035 | 554,990 | ||||||
| Legal & Professional Services Fees | 564,854 | 563,300 | ||||||
| Office Expense | 466,657 | 324,920 | ||||||
| Depreciation & Amortization | 192,374 | 196,943 | ||||||
| Other Operating Expenses | 134,827 | 95,989 | ||||||
| Total Expenses | 5,687,271 | 4,267,654 | ||||||
| OPERATING INCOME (LOSS) | (5,568,804 | ) | (3,898,977 | ) | ||||
| OTHER INCOME (EXPENSE) | ||||||||
| Interest Income | 35,178 | 40,107 | ||||||
| State Incentives | - | 154,568 | ||||||
| Change in fair value of derivative liabilities | - | (186,908 | ) | |||||
| Exchange Rate Gain (Loss) | 162 | - | ||||||
| Interest Expense | (3,966 | ) | (161,852 | ) | ||||
| Loss on Disposal of Assets | (36,733 | ) | (13,161 | ) | ||||
| Debt Discount Amortization | - | (358,280 | ) | |||||
| Total Other Income (Loss) | (5,359 | ) | (525,526 | ) | ||||
| LOSS BEFORE PROVISION FOR INCOME TAXES | (5,574,163 | ) | (4,424,503 | ) | ||||
| Provision for income Taxes | - | - | ||||||
| Net Loss | $ | (5,574,163 | ) | $ | (4,424,503 | ) | ||
| Preferred Dividends | (15,125 | ) | - | |||||
| Net Loss applicable to Common Stockholders | $ | (5,589,288 | ) | $ | (4,424,503 | ) | ||
| Net Loss per Common Share - Basic and Diluted | $ | (0.81 | ) | $ | (1.00 | ) | ||
| Weighted Average Number of Shares Outstanding - Basic and Diluted | 6,898,047 | 4,403,479 | ||||||
Sigma Labs, Inc.
Condensed Statements of Cash Flows
For the Periods Ended
(Unaudited)
December 31, 2018 | December 31, 2017 | |||||||
| OPERATING ACTIVITIES | ||||||||
| Net Loss | $ | (5,574,163 | ) | $ | (4,424,503 | ) | ||
| Adjustments to reconcile Net Income (Loss) to Net Cash used in operating activities: | ||||||||
| Noncash Expenses: | ||||||||
| Depreciation and Amortization | 192,374 | 196,943 | ||||||
| Stock Based Compensation | 1,145,530 | 719,796 | ||||||
| Loss on Writeoff of Assets | 36,733 | 13,161 | ||||||
| Refund on Write-off of Asset | - | 15,700 | ||||||
| Gain/Loss on Change in Derivative Balance | - | 186,908 | ||||||
| Original Issue Discount Amortization | - | 88,442 | ||||||
| Debt Discount Amortization | - | 358,280 | ||||||
| Change in assets and liabilities: | ||||||||
| Accounts Receivable, net | 65,738 | 183,698 | ||||||
| Interest Receivable | 34,390 | - | ||||||
| Inventory | (24,844 | ) | (5,464 | ) | ||||
| Prepaid Assets | (1,652 | ) | (16,957 | ) | ||||
| Accounts Payable | 116,604 | (11,291 | ) | |||||
| Deferred Revenue | 15,818 | 32,365 | ||||||
| Accrued Expenses | 230,501 | 24,529 | ||||||
| NET CASH USED IN OPERATING ACTIVITIES | $ | (3,762,971 | ) | $ | (2,638,393 | ) | ||
| INVESTING ACTIVITIES | ||||||||
| Purchase of Furniture and Equipment | (79,116 | ) | (69,463 | ) | ||||
| Purchase of Intangible Assets | (149,409 | ) | (70,997 | ) | ||||
| Notes Receivable | 632,197 | (788,500 | ) | |||||
| NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES | 403,672 | (928,960 | ) | |||||
| FINANCING ACTIVITIES | ||||||||
| Proceeds from issuance of Series B Convertible Preferred & Warrants | 1,000,000 | - | ||||||
| Proceeds from issuance of Series C Convertible Preferred & Warrants | 350,000 | - | ||||||
| Proceeds from issuance of Common Stock and Warrants | 2,040,100 | 5,823,300 | ||||||
| Less Offering Costs | (443,700 | ) | (750,664 | ) | ||||
| Payments on Notes Payable | - | (500,000 | ) | |||||
| Proceeds from Exercise of Warrants | 192,132 | 112,000 | ||||||
| Dividends on Preferred | (15,125 | ) | - | |||||
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 3,123,407 | 4,684,636 | ||||||
| NET CASH INCREASE (DECREASE) FOR PERIOD | $ | (235,892 | ) | $ | 1,117,283 | |||
| CASH AT BEGINNING OF PERIOD | $ | 1,515,674 | $ | 398,391 | ||||
| CASH AT END OF PERIOD | $ | 1,279,782 | $ | 1,515,674 | ||||
| (0.21 | ) | $ | 0 | |||||
| Supplemental Disclosures: | ||||||||
| Noncash investing & financing activities disclosure: | ||||||||
| Write-off of Derivative Liability | $ | - | $ | (280,114 | ) | |||
| Conversion of conv debt for stock | $ | (50,000 | ) | $ | (408,566 | ) | ||
| Other noncash operating activities disclosure: | ||||||||
| Issuance of Common Stock for Services | $ | 256,264 | $ | 75,578 | ||||
| Disclosure of cash paid for: | ||||||||
| Interest | $ | 12,205 | $ | 89,348 | ||||
Sigma Labs, Inc.
Statement of Stockholders’ Equity
For The Twelve Months Ended December 31, 2018 and the Year Ended December 31, 2017
| Common Stock Shares | Common Stock Amount | Additional Paid in Capital | Accumulated Deficit | Totals | ||||||||||||||||
| Balance December 31, 2016 | 3,133,789 | $ | 3,135 | $ | 10,734,857 | $ | -9,760,954 | $ | 977,038 | |||||||||||
| Shares issued for Services at a price of $1.72 | 20,000 | 20 | 34,384 | 34,404 | ||||||||||||||||
| Shares issued for Services at a price of $3.25 | 5,232 | 5 | 16,999 | 17,004 | ||||||||||||||||
| Shares issued for Services at a price of $2.27 | 7,489 | 7 | 16,993 | 17,000 | ||||||||||||||||
| Shares issued for Services at a price of $2.07 | 8,213 | 8 | 16,992 | 17,000 | ||||||||||||||||
| Shares sold in Dawson & James Offering at a net price of $3.757 | 1,410,000 | 1,410 | 4,885,811 | 4,887,221 | ||||||||||||||||
| Warrants sold in Dawson & James Offering at a price of $0.13 | 183,300 | 183,300 | ||||||||||||||||||
| Warrents sold at a price of $.01 | 2,115 | 2,115 | ||||||||||||||||||
| Debt discount on notes payable | - | - | 0 | - | 0 | |||||||||||||||
| Shares Issued from exercise of Warrants | 141,000 | 141 | -141 | - | 0 | |||||||||||||||
| Shares forfeited | -8,250 | -8 | -9,822 | - | -9,830 | |||||||||||||||
| Fractional shares issued at reverse stock split | 1,178 | 1 | - | - | 1 | |||||||||||||||
| Shares Issued for Note Payables Conversions | 200,000 | 200 | 399,800 | 400,000 | ||||||||||||||||
| Shares Issued for Accrued Interest on Noter Payable (L1) | 4,278 | 4 | 8,552 | 8,556 | ||||||||||||||||
| Shares Issued from exercise of Warrants (L1) | 56,000 | 56 | 111,944 | 112,000 | ||||||||||||||||
| Writeoff of Derivative Liability upon note conversions | 280,114 | 280,114 | ||||||||||||||||||
| Stock options awarded to employees | 510,496 | 510,496 | ||||||||||||||||||
| Net loss for the twelve months ended December 31, 2017 | -4,424,503 | -4,424,503 | ||||||||||||||||||
| Balance December 31, 2017 | 4,978,929 | $ | 4,979 | $ | 17,192,394 | $ | -14,185,457 | $ | 3,011,916 | |||||||||||
| Shares issued for Services at a price of $1.72 | 23,256 | 23 | 39,977 | - | 40,000 | |||||||||||||||
| Shares issued for Services at a price of $1.2236 | 176,744 | 177 | 216,087 | - | 216,264 | |||||||||||||||
| Convertible Preferred Shares issued in PIPE | - | - | 877,499 | 877,499 | ||||||||||||||||
| Shares issued for Conversion of Preferred | 1,000,000 | 1,000 | -999 | - | 1 | |||||||||||||||
| Preferred Dividends Paid upon Conversion | -15,125 | -15,125 | ||||||||||||||||||
| Shares Issued for Note Payables Conversions | 25,000 | 25 | 49,975 | - | 50,000 | |||||||||||||||
| Shares Issued for Cashless Exchange of Warrants | 4,800 | 5 | -5 | - | 0 | |||||||||||||||
| Shares sold in DJames Public Offering at a net price of $0.895 | 2,040,000 | 2,040 | 1,720,360 | - | 1,722,400 | |||||||||||||||
| Series C Convertible Preferred Shares Issued | 346,500 | 346,500 | ||||||||||||||||||
| Shares issued for Conversion of Preferred | 350,000 | 350 | -350 | - | 0 | |||||||||||||||
| Shares Issued from exercise of Warrants | 177,900 | 178 | 191,954 | - | 192,132 | |||||||||||||||
| Stock options awarded to employees | - | - | 868,015 | - | 868,015 | |||||||||||||||
| Net loss for the Twelve months ended December 31, 2018 | 0 | 0 | 0 | -5,574,163 | -5,574,163 | |||||||||||||||
| Balance December 31, 2018 | 8,776,629 | $ | 8,777 | $ | 21,501,407 | $ | -19,774,745 | $ | 1,735,438 | |||||||||||